Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cytomegalovirus
Pharma
Merck's Prevymis outdoes Roche's Valcyte in toxicity measure
In testing Merck's Prevymis against Roche’s Valcyte in kidney transplant recipients, Prevymis showed comparable efficacy and a better safety profile.
Kevin Dunleavy
Oct 24, 2022 10:45am
VBI Vaccines touts positive phase 1 data for CMV vaccine
May 15, 2018 8:43am
FluMist, Heplisav-B and more—News of Note
Feb 21, 2018 8:46am
Vical’s Astellas-partnered CMV vaccine falls short in phase 3
Jan 22, 2018 3:32pm
Moderna unveils new infectious disease programs at JPM
Jan 9, 2018 9:13am
Vienna's Hookipa Biotech starts early CMV vaccine trial
Jul 26, 2016 1:59pm
